Taking a look at stock we notice that its last check on previous day was $4.85 and 5Y monthly beta was reading 0 with its price kept floating in the range of $4.6200 and $4.9800 on the day. Company’s P/E ratio for…
the trailing 12 months is 22.45. Considering stock’s 52-week price range provides that ACB hit a high price of $47.28 and saw its price falling to a low level of $3.93 during that period. Over a period of past 1-month, stock came losing -6.19% in its value.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with nil upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review ACB stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.
According to ratings assigned by 19 analysts at the scale of 1 to 5 with 1.00 representing a strong buy and 5.00 suggesting a strong sell; 14 of them are recommending Aurora Cannabis Inc. (ACB) as a Hold, while 3 are in view that stock is a Buy. Recommendation by None analysts for the stock is an Outperform while number of those analysts who rated the stock as Underperform is none, whereas 2 of them are considering the stock as a Sell. When taken as whole, stock gets a rating of Hold and that encourages the investors to exploit the opportunity and build their stake up in the company.
Digging deeper we become aware of the PEG ratio of the ACB stock which is currently positioned at 0. It further provides that stock’s current price level is 2.97% away from its 20-day simple moving average and is -30.77% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 40.85 while volatility remained at 1133% over the past week which changes to 9.23% when measuring it over the past month. Beta is valued at 0, while measure of average true range or ATR is currently at 0.49. In predicting price targets of as low as $5.15 and as high as $18, analysts are in agreement on assigning the stock over the next 12 months average price target of $8.75. Stock’s current price level is 6.19% above from estimated low price target while it is 271.13% below the estimated high; and even if the ACB’s share succeeded to reach the median price of $7.76, then the outlook of +60% could come to the excitement of the investors.
In comparing Aurora Cannabis Inc. (ACB)’s stock with other industry players reveals that stock’s latest price change of 0% and that of -88.99% over the past 12 months is in competing position with that of Abbott Laboratories (ABT) which saw its stock price raised by 3.35% in the recent trading and went through an increase of 34.71% in past 12-month trading. Industry’s another major player Medtronic Inc (MDT) has jumped 2.39% up in latest trading session, but over the past year has faced a rise of 6.29%, while Stryker Corp (SYK) is also down 0% however its price remained floating in the red at -88.99% over the same period. Aurora Cannabis Inc. has a P/E ratio of 22.45 against that of Abbott Laboratories’s 63.32 while Medtronic Inc is showing 34.51 for the same. On the other hand, the S&P 500 Index was up 0.52% in the early deals while the Dow Jones Industrial was dealing higher at 0.54%.
Having a second look at Aurora Cannabis Inc. (NYSE:ACB) provides that stock’s average daily trading volume for 3 months was…
Continue reading at STOCKREGISTER.com